Genomic Alterations in Acute Myeloid Leukemia in Routine Clinical Practice

Acute Myeloid Leukemia (AML), the most common acute leukemia in adults, is a genetically heterogeneous disease. Genomic alterations condition pathophysiology of AML. Nowadays, these changes are considered to be important biomarkers for risk stratification, treatment decisions (including new targeted drugs) and Minimal Residual Disease (MRD) monitoring during followup Positive MRD AML patients associated with higher relapse shorter overall survival compared negative individuals. Nevertheless, MRD-targets, diagnostic techniques, time points determination, analyzed material not standardized. Thus, integration testing individual routine practice still workin- progress. This review article comprehensively focuses on key molecular their utilization clinical practice, especially regarding assessment testing. Moreover, molecular-targeted therapies briefly summarized here.